Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P669: Human β-defensin 2 suppresses TNF-α secretion in human and mouse dendritic cells mediated by chemokine receptor-2ECCO '18 Vienna
Year: 2018
Authors:

N.S. Armbruster1, K. Sidelmann Brinch2, B. Andersen2, E.F. Stange1, N. Malek1, P. Nordkild3, J. Wehkamp1*

1University Hospital Tübingen, Internal Medicine I, Tübingen, Germany, 2Novozymes, Bagsvaerd, Denmark, 3Defensin Therapeutics, Copenhagen, Denmark

P670: Comparative efficacy on steroid-free remission of pharmacological therapies for moderate-to-severe ulcerative colitis: A systematic review and network meta-analysisECCO '18 Vienna
Year: 2018
Authors:

P. Paschos1,2, A. Katsoula3, O. Giouleme3*, A. Tsapas1,4

1Aristotle University, Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Thessaloniki, Greece, 2"Papageorgiou" Hospital, 1st Department of Internal Medicine, Thessaloniki, Greece, 3Aristotle University, Second Propedeutic Medical Department, Thessaloniki, Greece, 4University of Oxford, Harris Manchester College, Oxford, UK

P671: Calprotectin does not add accuracy to PRO2 for prediction of continuous clinical response in moderate-to-severe ulcerative colitis patients treated with golimumabECCO '18 Vienna
Year: 2018
Authors:

F. Cornillie1*, L. Peyrin-Biroulet2, J. Long3, G. Philip3

1Merck Sharpe and Dohme, Kriens, Switzerland, 2University Hospital of Nancy, University of Lorraine, Houdemont, France, 3Merck and Co., Inc., Kenilworth, USA

P672: Number needed to treat to achieve clinical response at week 8 along with response or remission at week 52 with ustekinumab treatment vs. placebo from the phase 3 UNITI Crohn’s disease studies, by populationECCO '18 Vienna
Year: 2018
Authors:

S. Ghosh1*, C. Gasink2, L.-L. Gao2, C. Obando2

1University of Birmingham, Birmingham, UK, 2Janssen Scientific Affairs, LLC, Horsham, USA

P673: Vedolizumab dose escalation as a way of recapturing response in patients with inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

M. Sierra Morales1,2*, S. Birdi1, M.A. Samaan1, C. Brown-Clarke1, J. Duncan1, A. Stanton1, I. Koumoutsos1, S. Anderson1, S. Ray1, J. Mawdsley1, J. Sanderson1, P.M. Irving1

1Guy's and St Thomas' NHS Foundation Trust, Department of Gastroenterology, London, UK, 2Hospital Universitario Ramón y Cajal, Gastroenterología y Hepatología, Madrid, Spain

P674: Clinical characteristics and management of Crohn’s disease in patients with residual disease after surgery compared with curative surgery: Results from PRACTICROHN studyECCO '18 Vienna
Year: 2018
Authors:

E. Domènech1*, M.D. Martín Arranz2, M. Iborra3, V. García4, A. Gutiérrez5, C. Taxonera6, L. Cea-Calvo7, C. Romero7, M. Barreiro-de Acosta8, B. Juliá7

1Hospital Universitari Germans Trias i Pujol and CIBERehd, Gastroenterology Unit, Badalona, Spain, 2Hospital Universitario La Paz, Gastroenterology Unit, Madrid, Spain, 3Servicio de Gastroenterologia, Hospital La Fe, Valencia, Spain, 4Hospital Universitario Reina Sofia, Unidad Clinica de Aparato Digestivo, Cordoba, Spain, 5Hospital General Universitario Alicante, Gastroenterology Unit, Alicante, Spain, 6Hospital Clinico San Carlos, Gastroenterology Unit, Madrid, Spain, 7MSD Spain, Medical Department, Madrid, Spain, 8Complejo Hospitalario Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain

P675: Follow-up ileocolonoscopy is underused in Crohn’s disease patients after ileocecal resection despite higher total and inpatient health care costs compared with controls without resectionECCO '18 Vienna
Year: 2018
Authors:

A. Schoepfer1, S. Vavricka2*, B. Brüngger3, E. Blozik3, J. Celeiro4, T. Greuter2, C. Bähler3

1University Hospital Lausanne, Division of Gastroenterology and Hepatology, Lausanne, Switzerland, 2University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland, 3Helsana Group, Department of Health Sciences, Zurich, Switzerland, 4Triemli Hospital Zurich, Division of Surgery, Zurich, Switzerland

P676: Correlation of lipid levels with reduction in inflammation in patients with ulcerative colitis: Data from the tofacitinib OCTAVE clinical trialsECCO '18 Vienna
Year: 2018
Authors:

B.G. Feagan1, C.Y. Ha2, P.R. Taub3, D. Quirk4, C.I. Nduaka4, L. Salese4, G. Chan4, G.S. Friedman4, W. Wang4, C. Su4, W. Reinisch5*

1Western University, Robarts Clinical Trials, London, ON, Canada, 2Cedars-Sinai Medical Center, Inflammatory Bowel Disease Center, Division of Digestive Diseases, Los Angeles, CA, USA, 3UC San Diego School of Medicine, Division of Cardiovascular Medicine, La Jolla, CA, USA, 4Pfizer Inc., Collegeville, PA, USA, 5Medical University of Vienna, Dept Internal Medicine III, Vienna, Austria

P677: Azathioprine dosing and metabolite measurement in paediatric inflammatory bowel disease—does one size fit all?ECCO '18 Vienna
Year: 2018
Authors:

R. Tresman*, M. Mutalib, J. Kammermeier, R. Vora

Evelina London Children's Hospital, London, UK

P678: Risk of malnutrition in patients with inflammatory bowel diseases: Results from an Italian multi-centre observational cross-sectional studyECCO '18 Vienna
Year: 2018
Authors:

C. Viganò1*, A. Losco2, I. Bergna1, G. Meucci3, A. Amato4, GSMII (Gruppo di Studio per le Malattie Infiammatorie Intestinali)

1UOC Gastroenterologia ASST Monza Ospedale San Gerardo - International Center for Digestive Health University of Milan Bicocca, UOC Gastroenterologia ASST Monza, Monza, Italy, 2San Paolo Hospital ASST Santi Paolo e Carlo, UO Medicina VI Hepatology and Gastroenterology, Milano, Italy, 3San Giuseppe Hospital, Division of Gastroenterology, Milano, Italy, 4Valduce Hospital, Division of Gastroenterology, Como, Italy

P679: Risk factors for disease relapse after stepping down from combination to anti-TNF monotherapy in children with IBDECCO '18 Vienna
Year: 2018
Authors:

A. Yerushalmy-Feler*, S. Cohen

“Dana-Dwek” Children's Hospital, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, The Pediatric Gastroenterology Unit, Tel Aviv, Israel

P680: Machine learning (ML) in RCU-operated patients: Can we predict postoperative complications?ECCO '18 Vienna
Year: 2018
Authors:

L. Sofo*, P. Caprino, A.E. Potenza, F. Sacchetti, C.A. Schena

Fondazione Policlinico Gemelli, Rome, Italy

P681: Systematic review and meta-analysis of the safety and efficacy of intra-fistular injections of mesenchymal stem cells in clinical trials and observational cohort studiesECCO '18 Vienna
Year: 2018
Authors:

R. Ciccocioppo1*, C. Klersy2, D. Leffler3, R. Rogers3, D. Bennett3, G.R. Corazza4

1University of Verona, Department of Medicine, Verona, Italy, 2Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, 3Takeda Pharmaceutical Company Limited, Boston, USA, 4Fondazione IRCCS Policlinico San Matteo, Department of Clinical Medicine I, Pavia, Italy

P682: Role of laboratory markers in paediatric inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

R. Shentova*, P. Yaneva, M. Baycheva, P. Hadjiiski, D. Kofinova, C. Zhelev

University Paediatric Hospital “Prof. Ivan Mitev”, Gastroenterology and Hepatology, Sofia, Bulgaria

P683: Maintenance of deep remission in patients with ulcerative colitis treated with thiopurines after withdrawal of the drug: Perspective real-life experience of a single centreECCO '18 Vienna
Year: 2018
Authors:

M. Mazza*, C. Praticò, M. Salice, A. Calafiore, L. Calandrini, C. Calabrese, M. Campieri, F. Rizzello, P. Gionchetti

Policlinico Sant'Orsola Malpighi, Bologna, Italy

P684: Sleep disturbances in IBD patients without sedative therapyECCO '18 Vienna
Year: 2018
Authors:

G.E. Gilca-Blanariu1,2*, G. Stefanescu1,2, M. Ciocoiu2

1''Sf Spiridon'' County Clinical Emergency Hospital, Gastroenterology, Iasi, Romania, 2''Grigore T. Popa'' University of Medicine and Pharmacy, Iasi, Romania

P685: Patient’s performance and feedback by using home test faecal calprotectin as an objective reported outcomeECCO '18 Vienna
Year: 2018
Authors:

S.C. Wei*

National Taiwan University Hospital and College of Medicine, Department of Internal Medicine, Taipei, Taiwan

P686: Endoscopic follow-up and therapeutic attitude after ileocolonic resection in a nationwide Spanish cohort of Crohn’s disease patients: PRACTICROHN studyECCO '18 Vienna
Year: 2018
Authors:

M. Barreiro-de Acosta1*, V. García2, A. Gutiérrez3, M.D. Martín Arranz4, M. Iborra5, C. Taxonera6, C. Romero7, B. Juliá7, L. Cea-Calvo7, E. Domènech8

1Complejo Hospitalario Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain, 2Hospital Universitario Reina Sofia, Unidad Clinica de Aparato Digestivo, Cordoba, Spain, 3Hospital General Universitario Alicante, Gastroenterology unit, Alicante, Spain, 4Hospital Universitario La Paz, Gastroenterology Unit, Madrid, Spain, 5Servicio de Gastroenterologia, Hospital La Fe, Valencia, Spain, 6Hospital Clinico San Carlos, Gastroenterology Unit, Madrid, Spain, 7MSD Spain, Medical Department, Madrid, Spain, 8Hospital Universitari Germans Trias i Pujol and CIBERehd, Gastroenterology Unit, Badalona, Spain

P687: Female sex is associated with discontinuation of subcutaneous anti-TNF therapy for side effects in inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

J. Schultheiss*, E. Lamers, E. Brand, H. Fidder

UMC Utrecht, Gastroenterology, Utrecht, The Netherlands

P688: Demographic, clinical, and therapeutic characteristics of a cohort of 238 patients with ulcerative colitis from two medical centres from UruguayECCO '18 Vienna
Year: 2018
Authors:

M.J. Luciano1, A. Noria2, B. Iade1,3*

1Hospital de Clínicas, Gastroenterology, Montevideo, Uruguay, 2Hospital de Clnicas, Metodos, Montevideo, Uruguay, 3Grupo Uruguayo de Trabajo en Enfermedad Inflamatoria IntestinalL, Montevideo, Uruguay